Claims for Patent: 9,139,634

Summary for Patent: 9,139,634

Title:	Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
Abstract:	This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-.alpha.).
Inventor(s):	Morrison; Sherie L. (Los Angeles, CA), Huang; Tzu-Hsuan (Houston, TX), Xuan; Caiyun (Los Angeles, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	12/678,981
Patent Claims:	1. A method of inhibiting growth and/or proliferation of a cancer cell, said method comprising contacting said cancer cell with a chimeric construct comprising a type I interferon attached to a full-length antibody that binds to a tumor-associated antigen, wherein said antibody is attached to said interferon by a peptide linker that is resistant to proteolysis, wherein the amino acid sequence of said peptide linker is SGGGGS (SEQ ID NO:62) or AEAAAKEAAAKAGS (SEQ ID NO:63). 2. The method of claim 1, wherein said cancer cell is selected from the group consisting of a cell in a solid tumor, a metastatic cell, a breast cancer cell, and a B cell lymphoma. 3. The method of claim 1, wherein said cancer cell is cell produced by a cancer selected from the group consisting of a B cell lymphoma, lung cancer, a bronchus cancer, a colorectal cancer, a prostate cancer, a breast cancer, a pancreas cancer, a stomach cancer, an ovarian cancer, a urinary bladder cancer, a brain or central nervous system cancer, a peripheral nervous system cancer, an esophageal cancer, a cervical cancer, a melanoma, a uterine or endometrial cancer, a cancer of the oral cavity or pharynx, a liver cancer, a kidney cancer, a biliary tract cancer, a small bowel or appendix cancer, a salivary gland cancer, a thyroid gland cancer, a adrenal gland cancer, an osteosarcoma, a chondrosarcoma, a liposarcoma, a testes cancer, and a malignant fibrous histiocytoma. 4. The method of claim 1, wherein said contacting comprises administration via a route selected from the group consisting of systemic administration, administration directly into a tumor site, and intravenous administration. 5. The method of claim 1, wherein said cancer cell is a cancer cell in a human. 6. The method of claim 1, wherein said cancer cell is a cancer cell in a non-human mammal. 7. The method of claim 1, wherein said antibody is attached to said interferon by a peptide linker wherein the amino acid sequence of said linker is SGGGGS (SEQ ID NO:62). 8. The method of claim 1, wherein said antibody specifically binds a tumor associated antigen selected from the group consisting of CD20, HER3, HER2/neu, mucin 1 (MUC-1), G250, mesothelin, gp100, tyrosinase, and melanoma-associated antigen (MAGE). 9. The method of claim 1, wherein said antibody is an antibody that binds CD20. 10. The method of claim 1, wherein said antibody is an antibody that comprises the variable regions for anti-CD20 (Rituximab). 11. The method of claim 1, wherein said antibody is an antibody selected form the group consisting of rituximab, IF5, B1, 1H4, CD19, B4, B43, FVS191, hLL2, LL2, RFB4, M195, HuM195, AT13/5, trastuzumab, 4D5, HuCC49, HUCC39.DELTA.CH2 B72.3, 12C10, IG5, H23, BM-2, BM-7, 12H12, MAM-6, HMFG-1. 12. The method of claim 7, wherein said antibody is an antibody that binds to CD20. 13. The method of claim 7, wherein said antibody is an antibody that binds to HER2. 14. The method according to any one of claim 12 or 13, wherein said interferon is IFN-.alpha.. 15. The method according to any one of claim 12 or 13, wherein said interferon is IFN-.beta.. 16. The method of claim 1, wherein said antibody is attached to said interferon by a peptide linker wherein the amino acid sequence of said linker is AEAAAKEAAAKAGS (SEQ ID NO:63).

Details for Patent 9,139,634

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2027-09-21
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2027-09-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-09-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-09-21